Plenary Sessions

Lecture Topic: Therapuetic strategies for breast cancer chemoprevention

Prof. Paolo Ciana, PhD

paolociana1.jpg - Speakers

Paolo Ciana, received his laurea degree with honor in Biological Sciences in 1988 at the University of Pavia, the Ph.D. in Experimental Hematology in 1995 at the University of Milano and the Specialization in Applied Genetics in 1997 at the University of Pavia. He is currently Associate Professor at the Department of Pharmacological Sciences at the University of Milan. He has more than two decades experience in the study of nuclear receptors in physiology and oncogenesis through a combined biochemical, pharmacological, molecular biology and in vivo imaging approach. In the last 15 years, he has developed a multi-technological research strategy based on in vivo imaging, transcriptomic and animal transgenesis with reporter genes, to study physiological and pathogenetic processes (mainly oncogenesis) in vivo; his current research in the mammary oncogenesis aims, through the application of these methodologies, at identifying the molecular events driving the breast cancer progression and to suggest innovative  therapeutic strategies for the cure of this disease. Paolo Ciana is co-author of 115 publications (international publications in "peer reviewed" journals, contribution to book chapters and patents); H-index=35 (google scholar), 4651 citations. For his research in Biotechnology and Pharmacology he was awarded of the Biotechnological Research Prize of the University of Milano 2002, Galeno Prize 2003, Italian Society of Pharmacology and Farmindustria Award 2004, “Emilio Marmo” Prize of the Italian Society of Pharmacology for the best scientific contribution 2005 and of the international prize Eurotox/HSI/P&G Animal Welfare and Alternative Awards 2006. His research has been continuously supported by EU, Italian Telethon, Italian Association for Cancer Research and Italian Ministry of University and Research. He is co-founder of TOP s.r.l. a spin-off of the University of Milan. 

 

Lecture Topic: PSA SCREENING: The never-ending controversy

Jasmin Bektić, MD, PhD

Priv.-Doz. Dr. Jasmin Bektic, FEBU[6973].jpg - Speakers

Jasmin Bektić, MD – PhD is serving as the Associate Professor in the Department of Urology, Innsbruck Medical University. He is a member of the European Association of Urology (EAU) and Österreichische Gesellschaft für Urologie und Andrologie (ÖGU). Dr. Jasmin Bektić was born and raised in Tuzla, Bosnia and Herzegovina, where he graduated from elementary school and high school, but also started his studies at the School of Medicine, University of Tuzla. He then, in 1994, continued his education at the School of Medicine in Innsbruck. He graduated in 2001 from School of Medicine, University of Innsbruck and attended postdoctoral studies at Department of Urology, Medical University Innsbruck. Dr. Jasmin Bektić has gained expertise in Gene Expression, Cancer and Cancer Therapy and has more than 130 publications. His experience includes contribution to 9 clinical studies mostly focused on anticancer drug therapies used to treat prostate cancer. Dr. Bektić was awarded the Best poster award from the European Association of Urology and from the European Association for Cancer Research. He also received the acknowledgment: "Förderungspreis des Landes Tirol für Wissenschaft 2006".

Lecture topic: Cancer Registry; Key of Improving Cancer Care

cancer registry.png - Plenary Sessions

cr1.png - Plenary Sessions
cr.png - Plenary Sessions

Cancer is a generic term for a large group of diseases characterized by the growth of abnormal cells beyond their usual boundaries. Cancer is the second leading cause of death globally and is estimated to account for 9.6 million death in 2018. Bosnia and Herzegovina experiences the devastating impact that cancer places on its population too. According to the WHO 20% of deaths in Bosnia and Herzegovina can be attributed to cancer, a number that is above the global average and it shows a rising trend. Higher incidence and mortality rates of cancer weigh heavily on both government and family. It is therefore vital that authorities establish and sustain comprehensive cancer control strategies such as cancer registries. Cancer Registries are centers for systematic gathering, storing, analyzing, interpretation, and presentation of data on cancer incidence and survival of cancer patients. Registries play a critical role in cancer surveillance, which tells us where we are in the efforts to reduce the cancer burden. The importance of cancer registries lies in the fact that they collect accurate and complete cancer data that can be used for cancer control and epidemiological research, public health program planning, and patient care improvement. To share their experiences and talk about the importance of these registries, and how to implement them in Bosnia and Herzegovina we will talk with our compelling panelists: - Vesna Zadnik, MD, PHD – Director of one of the oldest population – based cancer registries in Europe “The Cancer Registry of Republic of Slovenia”, Mrs Zadnik carries out detail epidemiology analysis in elucidate a certain condition and keeps the general and the political public informed. - Mario Šekerija, MD, PHD – Epidemiologist Head of Croatian National Cancer Registry and also a leader of a iPAAC (Innovative Partnership for Action Against Cancer) work packages.

H.E. Mr. Lars-Gunnar Wigemark is going to give the opening remarks about general healthcare reform in Bosnia Herzegovina for the ECL session at SaMED 2019. 

We hope our session is going to be one of the first steps in establishing Cancer Registry in Bosnia and Herzegovina!

Lecture topic: Rethinking the brain drain; a non zero-sum game

bd.jpg - Plenary Sessions

 As the phrase „crisis in human resources“ might seem somewhat aggrandizement of the issues being faced by the global health sector, the recent data shows that its use may very well be legitimized. According to a 2006 WHO report, the world is facing an estimated 4,3 million shortage of doctors, nurses and midwives.
The antecedent changes in the global health dynamics have sparked a new, more intense wave of health workforce migration in the past decade.

The challenge of globalization and opening of borders for work market liberation, give rise to questions about sustainable development of LEDCs, and a rising dependency of high income countries on IMG's.
So the problem inevitably presents itself — how do we manage the oncoming pressures of doctor shortages in the lower income countries, brought on by those in the higher income countries, in a manner that can be equated to humanitarian negligence ?

To talk about this and gives us a unique frame of reference to this specific point are our compelling panelists:

• Dobrila Govedarica - As the Director of Open Society Fund BiH, Mrs Dobrila has had much experience with young people who have wanted to go abroad in search of a better education or opportunity.
• Selma Selimović, MD a researcher in the field of Ageing and Regenerative Medicine who received her MD at University of Sarajevo Medical school and a masters degree at Rollins school of public health at Emory University.
• Ajla Šunje, MD who left Bosnia as a refugee child, and later went on to pursue her medical degree in the US, but decided to return to her homeland where she now works as a director of the Chicago Vein Institute-Sarajevo.

By telling their personal stories and experiences along with the more general rendition of factors which come into play, we are looking to gain clarity and insight into a very intricate subject of medical migration.
The panel itself will feature a four piece discussion focusing on
1) Global patterns of migration and what can we learn from them
2) Challenges and perils awaiting every young MD when deciding to move abroad
3) The Anchor Factor —Grounds to stay
4) The non zero-sum game: Can we all win?